-
平臺(tái)編號(hào)：bio-68321
-
國(guó)際編號(hào)：CRL-2577?
-
細(xì)胞信息： RKO
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
RKO
運(yùn)輸方式：凍存運(yùn)輸
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
ATCC Number：CRL-2577?
相關(guān)疾?。耗[瘤
細(xì)胞形態(tài)：上皮樣
數(shù)量：大量
器官來(lái)源：結(jié)腸
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
規(guī)格：10mg Designations: RKO
Depositors: ?MC Hollander, AJ Fornace
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens deposited as human
Morphology:epithelial
Source: Organ: colon
Disease: carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:urokinase receptor (u-PAR) [51462 ]
Tumorigenic:Yes
Oncogene:p53 + (wild type)
DNA Profile (STR):Amelogenin: X
CSF1PO: 8, 10
D13S317: 8, 11
D16S539: 12, 13
D5S818: 11, 13
D7S820: 8, 10
THO1: 6, 10
TPOX:11
vWA: 15, 16, 17
Comments:RKO is a poorly differentiated colon carcinoma cell line developed by Michael Brattain.
RKO cells contain wild-type p53 but lack endogenous human thyroid receptor nuclear receptor (h-TRbeta1). The level of p53 protein is higher in RKO (ATCC CRL-2577 ) cells than in RKO-E6 (ATCC CRL-2578 ) cells. [53331 ]
The RKO cell line is the parental cell line (isogenic) of RKO-E6 (ATCC CRL-2578 ) and RKO-A545-1 (ATCC CRL-2579 ). It can be used as the control cell line for investigating the effects of p53 and gadd45 on cellular parameters.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2 ), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:12 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2578
derivative:ATCC CRL-2579
References: 51462: Boyd D, et al. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 48: 3112-3116, 1988. PubMed: 2835152
51463: Smith ML, et al. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059, 1995. PubMed: 7700629
53329: Brattain MG, et al. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev. 3: 177-191, 1984. PubMed: 6437669
53331: Bhat MK, et al. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J. Biol. Chem. 272: 28989-28993, 1997. PubMed: 9360971
生長(zhǎng)狀態(tài)：貼壁生長(zhǎng)
ATCC Number：CRL-2577?
相關(guān)疾?。耗[瘤
細(xì)胞形態(tài)：上皮樣
數(shù)量：大量
器官來(lái)源：結(jié)腸
是否是腫瘤細(xì)胞：0
物種來(lái)源：人
規(guī)格：10mg Designations: RKO
Depositors: ?MC Hollander, AJ Fornace
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Homo sapiens deposited as human
Morphology:epithelial
Source: Organ: colon
Disease: carcinoma
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Receptors:urokinase receptor (u-PAR) [51462 ]
Tumorigenic:Yes
Oncogene:p53 + (wild type)
DNA Profile (STR):Amelogenin: X
CSF1PO: 8, 10
D13S317: 8, 11
D16S539: 12, 13
D5S818: 11, 13
D7S820: 8, 10
THO1: 6, 10
TPOX:11
vWA: 15, 16, 17
Comments:RKO is a poorly differentiated colon carcinoma cell line developed by Michael Brattain.
RKO cells contain wild-type p53 but lack endogenous human thyroid receptor nuclear receptor (h-TRbeta1). The level of p53 protein is higher in RKO (ATCC CRL-2577 ) cells than in RKO-E6 (ATCC CRL-2578 ) cells. [53331 ]
The RKO cell line is the parental cell line (isogenic) of RKO-E6 (ATCC CRL-2578 ) and RKO-A545-1 (ATCC CRL-2579 ). It can be used as the control cell line for investigating the effects of p53 and gadd45 on cellular parameters.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2 ), 5%
Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:12 is recommended
Medium Renewal: Every 2 to 3 days
Remove medium, and rinse with 0.25% trypsin, 0.03% EDTA solution. Remove the solution and add an additional 1 to 2 ml of trypsin-EDTA solution. Allow the flask to sit at room temperature (or at 37C) until the cells detach.
Add fresh culture medium, aspirate and dispense into new culture flasks.
Preservation: culture medium 95%; DMSO, 5%
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
derivative:ATCC CRL-2578
derivative:ATCC CRL-2579
References: 51462: Boyd D, et al. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res. 48: 3112-3116, 1988. PubMed: 2835152
51463: Smith ML, et al. Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10: 1053-1059, 1995. PubMed: 7700629
53329: Brattain MG, et al. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev. 3: 177-191, 1984. PubMed: 6437669
53331: Bhat MK, et al. Tumor suppressor p53 is a negative regulator in thyroid hormone receptor signaling pathways. J. Biol. Chem. 272: 28989-28993, 1997. PubMed: 9360971
